99 related articles for article (PubMed ID: 69489)
21. Serum-derived immunosuppressive substances. III. Regulation of the immune response by human serum alpha-globulin fractions: the dose-response relationship.
Habicht GS; Miller F
Int Arch Allergy Appl Immunol; 1977; 55(1-6):239-46. PubMed ID: 73512
[TBL] [Abstract][Full Text] [Related]
22. In vitro generation of suppressor cell activity: suppression of in vitro induction if cell-mediated cytotoxicity.
Hodes RJ; Hathcock KS
J Immunol; 1976 Jan; 116(1):167-77. PubMed ID: 128570
[TBL] [Abstract][Full Text] [Related]
23. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
24. Suppressor cells in tumor-bearing mice capable of nonspecific blocking of in vitro immunization against transplant antigens.
Eggers AE; Wunderlich JR
J Immunol; 1975 May; 114(5):1554-6. PubMed ID: 123545
[TBL] [Abstract][Full Text] [Related]
25. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
Williams RM; Germain RN; Benacerraf B
J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
[TBL] [Abstract][Full Text] [Related]
26. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
Ting CC; Law LW
J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
[TBL] [Abstract][Full Text] [Related]
27. Immunoregulatory pathways in adult responder mice. II. Regulation of delayed-type hypersensitivity responses by GAT-specific suppressor factors present in GAT-tolerant adult responder mice.
Jenkins MK; Waltenbaugh C; Miller SD
J Immunol; 1985 Jan; 134(1):114-21. PubMed ID: 3155459
[TBL] [Abstract][Full Text] [Related]
28. The specificity of concomitant tumor immunity at large tumor volumes.
Deckers PJ; Pardridge DH; Wang BS; Mannick JA
Cancer Res; 1976 Oct; 36(10):3690-4. PubMed ID: 953994
[TBL] [Abstract][Full Text] [Related]
29. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
[TBL] [Abstract][Full Text] [Related]
30. Immunoregulatory T cells in tumor immunity.
Terabe M; Berzofsky JA
Curr Opin Immunol; 2004 Apr; 16(2):157-62. PubMed ID: 15023407
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive properties of electrophoretically "slow" and "fast" form alpha 2-macroglobulin. Effects on cell-mediated cytotoxicity and (allo-) antigen-induced T cell proliferation.
Petersen CM; Ejlersen E; Moestrup SK; Jensen PH; Sand O; Sottrup-Jensen L
J Immunol; 1989 Jan; 142(2):629-35. PubMed ID: 2463311
[TBL] [Abstract][Full Text] [Related]
32. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
33. Reversal of SV40 tumor-mediated suppression of spleen cell cytotoxicity by antibody.
Prather SO; Lausch RN
J Immunol; 1977 Jan; 118(1):203-10. PubMed ID: 187698
[TBL] [Abstract][Full Text] [Related]
34. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
[TBL] [Abstract][Full Text] [Related]
35. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes.
Fan J; Bonavida B
J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189
[TBL] [Abstract][Full Text] [Related]
36. Cell-mediated immunity to H-2 antigens. Characteristics of the effector cells as detected in the microcytotoxicity assay.
Trostmann H; Pfizenmaier K; Wagner H; Röllinghoff M
Transplantation; 1976 Jun; 21(6):446-53. PubMed ID: 1084606
[TBL] [Abstract][Full Text] [Related]
37. Studies on the cytotoxic effect of in vivo and in vitro immunized lymphocytes on liver target cells.
Warnatz H; Scheiffarth F; Schmeissner R
Clin Exp Immunol; 1975 Aug; 21(2):250-8. PubMed ID: 1081024
[TBL] [Abstract][Full Text] [Related]
38. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
39. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
40. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells.
Gooding LR
J Immunol; 1977 Mar; 118(3):920-7. PubMed ID: 191529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
